Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Wyeth Plant Goes To Newcomer Akrimax

January 21, 2008 | A version of this story appeared in Volume 86, Issue 3

Wyeth has sold its finished drug manufacturing and packaging plant in Rouses Point, N.Y., to Akrimax Pharmaceuticals, a new drug company. The sale agreement includes a transition period lasting until the end of 2009. During that time, Akrimax plans to introduce its own drugs and contract-manufactured products into the facility. The plant employs nearly 800 people. The sale does not include a 90-employee chemical development pilot plant, which Wyeth will continue to operate.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.